Scribe Therapeutics, Inc. 最新财务报告显示,该公司在2026年第二季度录得净亏损650万美元,折合每股亏损2.62美元。相较于2025年同期990万美元的净亏损及每股4.08美元的亏损水平,本季度亏损幅度明显收窄,财务状况呈现改善趋势。
Scribe Therapeutics, Inc. 最新财务报告显示,该公司在2026年第二季度录得净亏损650万美元,折合每股亏损2.62美元。相较于2025年同期990万美元的净亏损及每股4.08美元的亏损水平,本季度亏损幅度明显收窄,财务状况呈现改善趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.